(UroToday.com) Current prostate-specific antigen (PSA) screening guidelines suggest an individualized approach and shared decision-making model based on patient preference and certain risk factors such as family history or race. The clinical trials that largely have guided screening recommendations notably either did not report race or did not enroll a significant proportion of self-identified African American patients, and none of these enrolled patients were younger than 55 years of age. It is well-documented that when prostate cancer is diagnosed in African American men, it is diagnosed at a higher stage, younger age, and is associated with higher rates of poor disease outcomes.